Pluvicto是一种采用靶向PSMA的放射配体药物的诊疗方法,通过靶向PSMA的小分子药物PSMA-617与放射性同位素 177 Lu通过配体偶联。 177 Lu-PSMA-617通过其PSMA靶向基团定位前列腺癌细胞群,在不殃及周边细胞的情况下,将其“携带”的放射性核素传递到前列腺癌细胞内,进行精准辐射。2018年,诺华以21亿美元收购Endocyte,而获得...
[ Lu]Lu-PSMA-617 is a new effective class of therapy and a potential alternative to cabazitaxel. Funding Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear Science and Technology Organization, Movember, The Distinguished Gentleman's Ride, It's a Bloke Thing...
Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[18F]FDG-discordant disease. Funding: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Prostate Cancer Foundation of Australia, Endocyte (a Novartis company), Australian Nuclear ...
Pluvicto是一种采用靶向PSMA的放射配体药物的诊疗方法,通过靶向PSMA的小分子药物PSMA-617与放射性同位素 177 Lu通过配体偶联。 177 Lu-PSMA-617通过其PSMA靶向基团定位前列腺癌细胞群,在不殃及周边细胞的情况下,将其“携带”的放射性核素传递到前列腺癌细胞内,进行精准辐射。2018年,诺华以21亿美元收购Endocyte,而获得...